CureVac Covid vaccine solely 47% efficient in early information, shares tank
Yves Herman | Newpaper24
The vaccine candidate demonstrated an interim efficacy of 47% towards Covid-19 illness “of any severity,” in response to a press launch. The corporate mentioned closing evaluation of the outcomes can be accomplished within the coming weeks.
The late-stage scientific trial of roughly 40,000 contributors throughout 10 international locations discovered excessive prevalence of virus variants, particularly the lambda pressure first detected in South America.
“Whereas we have been hoping for a stronger interim final result, we acknowledge that demonstrating excessive efficacy on this unprecedented broad variety of variants is difficult,” CEO Franz-Werner Haas mentioned in a press release. “As we’re persevering with towards the ultimate evaluation with a minimal of 80 further instances, the general vaccine efficacy could change.”
The examine additionally discovered various ranges of efficacy for various age teams, in response to the discharge.
CureVac can be engaged on a separate Covid vaccine candidate in partnership with GlaxoSmithKline. The businesses anticipate to enter scientific testing on that candidate within the third quarter of 2021, CureVac mentioned Wednesday.